AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.
Create a link to this page
Copy and paste this link tag into your Web page or blog:
2002 NOV 13 - (NewsRx.com & NewsRx.net) -- Aastrom Biosciences, Inc., (ASTM) announced the initiation of a collaborative agreement with Leland Stanford Junior University (Stanford) for an immunotherapeutic vaccine clinical study for multiple myeloma cancer patients.
The collaboration will combine Aastrom's dendritic cell vaccine technology with Stanford's cancer antigen technology to produce a cell-based treatment for multiple myeloma.
The clinical study will be conducted at Stanford University Medical Center under the direction of Ronald Levy, MD, chief, Division of Oncology at Stanford University Medical Center. Dr. Levy is the principal investigator and received a grant supporting this study from the U.S. National Institutes of Health, Grant Number CA49605, Project 6, titled, "Idiotype vaccination following allogeneic transplantation for the treatment of multiple myeloma."
"This collaboration represents an important development for Aastrom, as it moves our dendritic cell technology forward into the clinic in a very interesting format," stated Steven Wolff, MD, Aastrom. "Dr. Levy's protocol will attempt to harness the power of the immune system to attack a serious ...